90 related articles for article (PubMed ID: 15533297)
21. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
22. Current treatment for cutaneous leishmaniasis: a review.
Palumbo E
Am J Ther; 2009; 16(2):178-82. PubMed ID: 19300044
[TBL] [Abstract][Full Text] [Related]
23. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice.
Antimisiaris SG; Ioannou PV; Loiseau PM
J Pharm Pharmacol; 2003 May; 55(5):647-52. PubMed ID: 12831507
[TBL] [Abstract][Full Text] [Related]
24. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi.
de Oliveira-Silva F; de Morais-Teixeira E; Rabello A
Am J Trop Med Hyg; 2008 May; 78(5):745-9. PubMed ID: 18458308
[TBL] [Abstract][Full Text] [Related]
25. Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice.
Metwally DM; Al-Olayan EM; El-Khadragy MF; Alkathiri B
PLoS One; 2016; 11(8):e0161296. PubMed ID: 27537199
[TBL] [Abstract][Full Text] [Related]
26. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
27. Detection of anti-leishmanial effect of the Lucilia sericata larval secretions in vitro and in vivo on Leishmania tropica: first work.
Polat E; Cakan H; Aslan M; Sirekbasan S; Kutlubay Z; Ipek T; Ozbilgin A
Exp Parasitol; 2012 Oct; 132(2):129-34. PubMed ID: 22750454
[TBL] [Abstract][Full Text] [Related]
28. Effects of anti-Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae).
Anjili C; Langat B; Ngumbi P; Mbati PA; Githure J; Tonui WK
East Afr Med J; 2006 Feb; 83(2):72-8. PubMed ID: 16708877
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes.
Miguel DC; Yokoyama-Yasunaka JK; Andreoli WK; Mortara RA; Uliana SR
J Antimicrob Chemother; 2007 Sep; 60(3):526-34. PubMed ID: 17584801
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
31. Combination and monotherapy of Leishmania major infection in BALB/c mice using plant extracts and herbicides.
Makwali JA; Wanjala FM; Kaburi JC; Ingonga J; Byrum WW; Anjili CO
J Vector Borne Dis; 2012 Sep; 49(3):123-30. PubMed ID: 23135005
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A.
Tanaka AK; Valero VB; Takahashi HK; Straus AH
J Antimicrob Chemother; 2007 Mar; 59(3):487-92. PubMed ID: 17242034
[TBL] [Abstract][Full Text] [Related]
34. Oral metabolism and efficacy of Kalanchoe pinnata flavonoids in a murine model of cutaneous leishmaniasis.
Muzitano MF; Falcão CA; Cruz EA; Bergonzi MC; Bilia AR; Vincieri FF; Rossi-Bergmann B; Costa SS
Planta Med; 2009 Mar; 75(4):307-11. PubMed ID: 19085683
[TBL] [Abstract][Full Text] [Related]
35. Arylanthranilodinitriles: a new biaryl class of antileishmanial agents.
Singh FV; Vatsyayan R; Roy U; Goel A
Bioorg Med Chem Lett; 2006 May; 16(10):2734-7. PubMed ID: 16503140
[TBL] [Abstract][Full Text] [Related]
36. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
37. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation.
Schwartz J; Moreno E; Fernández C; Navarro-Blasco I; Nguewa PA; Palop JA; Irache JM; Sanmartín C; Espuelas S
Eur J Pharm Sci; 2014 Oct; 62():309-16. PubMed ID: 24964292
[TBL] [Abstract][Full Text] [Related]
38. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Gonçalves GS; Fernandes AP; Souza RC; Cardoso JE; de Oliveira-Silva F; Maciel FC; Rabello A; Ferreira LA
Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330
[TBL] [Abstract][Full Text] [Related]
39. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L. major in BALB/c mice.
Onyalo JA; Mwala DM; Anjili CO; Orago AS; Tonui WK
East Afr Med J; 2005 Apr; 82(4):193-7. PubMed ID: 16122087
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy assessment of pentamidine isethionate and diminazene aceturate in the chemotherapy of Trypanosoma brucei brucei infection in dogs.
Akpa PO; Ezeokonkwo RC; Eze CA; Anene BM
Vet Parasitol; 2008 Feb; 151(2-4):139-49. PubMed ID: 18155842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
